[1]陈若瑜,曹丹,张良.糖尿病视网膜病变药物治疗研究进展[J].眼科新进展,2022,42(3):244-248.[doi:10.13389/j.cnki.rao.2022.0050]
　CHEN Ruoyu,CAO Dan,ZHANG Liang.Advances in drug therapy for diabetic retinopathy[J].Recent Advances in Ophthalmology,2022,42(3):244-248.[doi:10.13389/j.cnki.rao.2022.0050]
点击复制

糖尿病视网膜病变药物治疗研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年3期
页码:
244-248
栏目:
文献综述
出版日期:
2022-03-05

文章信息/Info

Title:
Advances in drug therapy for diabetic retinopathy
作者:
陈若瑜; 曹丹; 张良
510515　广东省广州市，南方医科大学第二临床医学院（陈若瑜）；510080　广东省广州市，广东省人民医院眼科，广东省医学科学院（陈若瑜，曹丹，张良）
Author(s):
CHEN Ruoyu1; 2; CAO Dan2; ZHANG Liang2
1.The Second School of Clinical Medicine,Southern Medical University,Guangzhou 510515,Guangdong Province,China
2.Department of Ophthalmology,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,Guangzhou 510080,Guangdong Province,China
关键词:
糖尿病视网膜病变; 黄斑水肿; 药物治疗; 抗氧化剂
Keywords:
diabetic retinopathy;  macular edema;  drug therapy;  antioxidant
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2022.0050
文献标志码:
A
摘要:
糖尿病视网膜病变（DR）是慢性高血糖引起的视网膜微血管并发症。全身危险因素、炎症、氧化应激参与了DR的发生与发展。全视网膜光凝术是预防DR患者视力下降的一线治疗方法，但激光的破坏性会带来一系列眼部并发症。与激光治疗相比，药物治疗能够对DR病情发展的多个环节进行干预，同时也能更好地保留视网膜的解剖结构、减少激光相关并发症。本文从控制全身危险因素的药物、血管保护剂、抗炎药、抗氧化剂、中医中药、纳米药物等多个方面对DR的药物治疗研究进展进行综述，旨在为DR患者制定全面、多元化的治疗方案提供新思路。
Abstract:
Diabetic retinopathy (DR) is a retinal microvascular complication caused by chronic hyperglycemia. Systemic risk factors, inflammation, and oxidative stress are involved in the occurrence and development of DR. Panretinal photocoagulation is the first-line treatment for preventing vision loss in DR patients. However, the destructive nature of lasers can bring a series of ocular complications. Compared with laser therapy, drug therapy can intervene in multiple links of DR development. Meanwhile, it can preserve the anatomical structure of the retina and reduce laser-related complications. In order to provide new ideas for the comprehensive and diversified DR treatment plans, this article reviews the advances in drug therapy for DR from such aspects as drugs controlling systemic risk factors, vascular protectants, anti-inflammatory agents, antioxidants, traditional Chinese medicine, and nanomedicine.

参考文献/References:

［1］　CHEUNG N,MITCHELL P,WONG T Y.Diabetic retinopathy［J］.Lancet,2010,376(9735)：124-136.
［2］　YANG Q H,ZHANG Y,ZHANG X M,LI X R.Prevalence of diabetic retinopathy,proliferative diabetic retinopathy and non-proliferative diabetic retinopathy in Asian T2DM patients：a systematic review and Meta-analysis［J］.Int J Ophthalmol,2019,12(2)：302-311.
［3］　中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)［J］.中国实用内科杂志,2018,38 (4)：292-344.
Diabetes Society of Chinese Medical Association.Chinese guidelines for the prevention and treatment of type 2 diabetes (2017 edition)［J］.Chin J Pract Intern Med,2018,38 (4)：292-344.
［4］　FAN Y P,WU C T,LIN J L,HSIUNG C A,LIU H Y,LAI J N,et al.Metformin treatment is associated with a decreased risk of nonproliferative diabetic retinopathy in patients with type 2 diabetes mellitus：a population-based cohort study［J］.J Diabetes Res,2020,2020：9161039.
［5］　HAN J,LI Y,LIU X,ZHOU T,SUN H,EDWARDS P,et al.Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo［J］.PLoS One,2018,13(3)：e0193031.
［6］　ALEX A,LUO Q,MATHEW D,DI R,BHATWADEKAR A D.Metformin corrects abnormal circadian rhythm and Kir4.1 channels in diabetes［J］.Invest Ophthalmol Vis Sci,2020,61(6)：46.
［7］　HERAT L Y,MATTHEWS V B,RAKOCZY P E,CARNAGARIN R,SCHLAICH M.Focusing on sodium glucose cotransporter-2 and the sympathetic nervous system：potential impact in diabetic retinopathy［J］.Int J Endocrinol,2018,2018：9254126.
［8］　WAKISAKA M,NAGAO T.Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy［J］.Glycobiology,2017,27(8)：691-695.
［9］　CHO E H,PARK S J,HAN S,SONG J H,LEE K,CHUNG Y R.Potent oral hypoglycemic agents for microvascular complication：sodium-glucose cotransporter 2 inhibitors for diabetic retinopathy［J］.J Diabetes Res,2018,2018：6807219.
［10］　RAMOS H,BOGDANOV P,SAMPEDRO J,HUERTA J,SIM R,HERNNDEZ C.Beneficial effects of glucagon-like peptide-1 (glp-1) in diabetes-induced retinal abnormalities：involvement of oxidative stress［J］.Antioxidants (Basel),2020,9(9)：846.
［11］　HERNNDEZ C,BOGDANOV P,CORRALIZA L,GARCA-RAMREZ M,SOL-ADELL C,ARRANZ J A,et al.Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes［J］.Diabetes,2016,65(1)：172-187.
［12］　PANG B,ZHOU H,KUANG H.The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy［J］.Peptides,2018,100：123-126.
［13］　VILSBOLL T,BAIN S C,LEITER L A,LINGVAY I,MATTHEWS D,SIMO R,et al.Semaglutide,reduction in glycated haemoglobin and the risk of diabetic retinopathy［J］.Diabetes Obes Metab,2018,20(4)：889-897.
［14］　BAIN S C,KLUFAS M A,HO A,MATTHEWS D R.Worsening of diabetic retinopathy with rapid improvement in systemic glucose control：A review［J］.Diabetes Obes Metab,2019,21(3)：454-466.
［15］　OLA M S,ALHOMIDA A S,FERRARIO C M,AHMAD S.Role of tissue renin-angiotensin system and the chymase/angiotensin-( 1-12) axis in the pathogenesis of diabetic retinopathy［J］.Curr Med Chem,2017,24(28)：3104-3114.
［16］　WANG B,WANG F,ZHANG Y,ZHAO S H,ZHAO W J,YAN S L,et al.Effects of RAS inhibitors on diabetic retinopathy：a systematic review and meta-analysis［J］.Lancet Diabetes Endocrinol,2015,3(4)：263-274.
［17］　KAWASAKI R,KONTA T,NISHIDA K.Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes：a real-world observational analysis of a health claims database［J］.Diabetes Obes Metab,2018,20(10)：2351-2360.
［18］　KANG E Y,CHEN T H,GARG S J,SUN C C,KANG J H,WU W C,et al.Association of statin therapy with prevention of Vision-Threatening diabetic retinopathy［J］.JAMA Ophthalmol,2019,137(4)：363-371.
［19］　BEDI O,DHAWAN V,SHARMA P L,KUMAR P.Pleiotropic effects of statins：new therapeutic targets in drug design［J］.Naunyn Schmiedebergs Arch Pharmacol,2016,389(7)：695-712.
［20］　BUSIK J V.Lipid metabolism dysregulation in diabetic retinopathy［J］.J Lipid Res,2021,62：100017.
［21］　CHEW E Y,DAVIS M D,DANIS R P,LOVATO J F,PERDUE L H,GREVEN C,et al.The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes：the action to control cardiovascular risk in diabetes (ACCORD) eye study［J］.Ophthalmology,2014,121(12)：2443-2451.
［22］　SIM R,HERNNDEZ C.Fenofibrate for diabetic retinopathy［J］.Lancet,2007,370(960)：1667-1668.
［23］　PEARSALL E A,CHENG R,MATSUZAKI S,ZHOU K,DING L,AHN B,et al.Neuroprotective effects of PPARα in retinopathy of type 1 diabetes［J］.PLoS One,2019,14(2)：e0208399.
［24］　LIU Q,ZHANG X,CHENG R,MA J X,YI J,LI J.Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress-mediated Wnt/β-catenin pathway activation［J］.Cell Tissue Res,2019,376(2)：165-177.
［25］　WANG N,ZOU C,ZHAO S,WANG Y,HAN C,ZHENG Z.Fenofibrate exerts protective effects in diabetic retinopathy via inhibition of the ANGPTL3 pathway［J］.Invest Ophthalmol Vis Sci,2018,59(10)：4210-4217.
［26］　REID G,LOIS N.Erythropoietin in diabetic retinopathy［J］.Vision Res,2017,139：237-242.
［27］　XIE H,ZHANG C,LIU D,YANG Q,TANG L,WANG T,et al.Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy［J］.Diabetologia,2021,64(1)：211-225.
［28］　SAMSON F P,HE W,SRIPATHI S R,PATRICK A T,MADU J,CHUNG H,et al.Dual Switch mechanism of erythropoietin as an antiapoptotic and Pro-Angiogenic determinant in the retina［J］.ACS Omega,2020,5(33)：21113-21126.
［29］　BRETZ C A,RAMSHEKAR A,KUNZ E,WANG H,HARTNETT M E.Signaling through the erythropoietin receptor affects angiogenesis in retinovascular disease［J］.Invest Ophthalmol Vis Sci,2020,61(10)：23.
［30］　BOGDANOV P,SOL-ADELL C,HERNNDEZ C,GARCA-RAMREZ M,SAMPEDRO J,SIM-SERVAT O,et al.Calcium dobesilate prevents the oxidative stress and inflammation induced by diabetes in the retina of db/db mice［J］.J Diabetes Complications,2017,31(10)：1481-1490.
［31］　WANG Y,LU Y H,TANG C,XUE M,LI X Y,CHANG Y P,et al.Calcium dobesilate restores autophagy by inhibiting the VEGF/PI3K/AKT/mTOR signaling pathway［J］.Front Pharmacol,2019,10：886.
［32］　LIU J,LI S,SUN D.Calcium dobesilate and micro-vascular diseases［J］.Life Sci,2019,221：348-353.
［33］　BROEKHUIZEN L N,LEMKES B A,MOOIJ H L,MEUWESE M C,VERBERNE H,HOLLEMAN F,et al.Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus［J］.Diabetologia,2010,53(12)：2646-2655.
［34］　GIURDANELLA G,LAZZARA F,CAPORARELLO N,LUPO G,ANFUSO C D,EANDI C M,et al.Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE［J］.Biochem Pharmacol,2017,142：145-154.
［35］　SONG J H,CHIN H S,KWON O W,LIM S J,DRESS R G.Effect of sulodexide in patients with non-proliferative diabetic retinopathy：diabetic retinopathy sulodexide study (DRESS)［J］.Graefes Arch Clin Exp Ophthalmol,2015,253(6)：829-837.
［36］　GROSS J G,GLASSMAN A R,LIU D,SUN J K,ANTOSZYK A N,BAKER C W,et al.Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy：a randomized clinical trial［J］.JAMA Ophthalmol,2018,136(10)：1138-1148.
［37］　CHATZIRALLI I,DIMITRIOU E,THEODOSSIADIS G,KAZANTZIS D,THEODOSSIADIS P.Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema：long-term outcomes of a prospective study［J］.Acta Diabetol,2020,57(10)：1219-1225.
［38］　CAO G,XU X,WANG C,ZHANG S.Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation［J］.Eur J Ophthalmol,2020,30(1)：34-39.
［39］　CHEN H J,WANG C G,DOU H L,FENG X F,XU Y M,MA Z Z.Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy［J］.Ann Palliat Med,2020,9(1)：82-89.
［40］　SURESH R,YU H J,THOVESON A,SWISHER J,APOLINARIO M,ZHOU B,et al.Loss to follow-up among patients with proliferative diabetic retinopathy in clinical practice［J］.Am J Ophthalmol,2020,215：66-71.
［41］　CAMPOCHIARO P A,MARCUS D M,AWH C C,REGILLO C,ADAMIS A P,BANTSEEV V,et al.The port delivery system with ranibizumab for neovascular age-related macular degeneration：results from the randomized phase 2 ladder clinical trial［J］.Ophthalmology,2019,126(8)：1141-1154.
［42］　GONZALEZ V H,CAMPBELL J,HOLEKAMP N M,KISS S,LOEWENSTEIN A,AUGUSTIN A J,et al.Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema：analysis of protocol I data［J］.Am J Ophthalmol,2016,172：72-79.
［43］　CALLANAN D G,LOEWENSTEIN A,PATEL S S,MASSIN P,CORCóSTEGUI B,LI X Y,et al.A multicenter,12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema［J］.Graefes Arch Clin Exp Ophthalmol,2017,255(3)：463-473.
［44］　IGLICKI M,ZUR D,BUSCH C,OKADA M,LOEWENSTEIN A.Progression of diabetic retinopathy severity after treatment with dexamethasone implant：a 24-month cohort study the ’DR-Pro-DEX Study’［J］.Acta Diabetol,2018,55(6)：541-547.
［45］　BUSCH C,FRASER-BELL S,IGLICKI M,LUPIDI M,COUTURIER A,CHAIKITMONGKOL V,et al.Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant：2-year results［J］.Acta Diabetol,2019,56(12)：1341-1350.
［46］　AVERY R L,GORDON G M.Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema：a systematic review and meta-analysis［J］.JAMA Ophthalmol,2016,134(1)：21-29.
［47］　SCHMIDT-ERFURTH U,GARCIA-ARUMI J,BANDELLO F,BERG K,CHAKRAVARTHY U,GERENDAS B S,et al.Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA)［J］.Ophthalmologica,2017,237(4)：185-222.
［48］　LIN C M,TITCHENELL P M,KEIL J M,GARCIA-OCAA A,BOLINGER M T,ABCOUWER S F,et al.Inhibition of atypical protein kinase C reduces Inflammation-Induced retinal vascular permeability［J］.Am J Pathol,2018,188(10)：2392-2405.
［49］　YAO Y,LI R,DU J,LONG L,LI X,LUO N.Interleukin-6 and diabetic retinopathy：a systematic review and Meta-analysis［J］.Curr Eye Res,2019,44(5)：564-574.
［50］　TAN W,ZOU J L,YOSHIDA S,JIANG B,ZHOU Y D.Increased vitreal levels of interleukin-10 in diabetic retinopathy：a Meta-analysis［J］.Int J Ophthalmol,2020,13(9)：1477-1483.
［51］　CAMPA C.New anti-VEGF drugs in ophthalmology［J］.Curr Drug Targets,2020,21(12)：1194-1200.
［52］　HUANG D D,SHI G,JIANG Y,YAO C,ZHU C.A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications［J］.Biomed Pharmacother,2020,125：109767.
［53］　SEPAHI S,MOHAJERI S,HOSSEINI S M,KHODAVERDI E,SHOEIBI N,NAMDARI M,et al.Effects of crocin on diabetic maculopathy：a placebo-controlled randomized clinical trial［J］.Am J Ophthalmol,2018,190：89-98.
［54］　YANG X,HUO F,LIU B,LIU J,CHEN T,LI J,et al.Crocin inhibits oxidative stress and pro-inflammatory response of microglial cells associated with diabetic retinopathy through the activation of PI3K/Akt signaling pathway［J］.J Mol Neurosci,2017,61(4)：581-589.
［55］　GARCIA-MEDINA J J,RUBIO-VELAZQUEZ E,FOULQUIE-MORENO E,CASAROLI-MARANO R P,PINAZO-DURAN M D,ZANON-MORENO V,et al.Update on the effects of antioxidants on diabetic retinopathy：in vitro experiments,animal studies and clinical trials［J］.Antioxidants (Basel),2020,9(6)：561.
［56］　HAO G M,LV T T,WU Y,WANG H L,XING W,WANG Y,et al.The hippo signaling pathway：a potential therapeutic target is reversed by a Chinese patent drug in rats with diabetic retinopathy［J］.BMC Complement Altern Med,2017,17(1)：187.
［57］　SUN H H,CHAI X L,LI H L,JY T,JIANG K X,SONG X Z,et al.Fufang xueshuantong alleviates diabetic retinopathy by activating the PPAR signalling pathway and complement and coagulation cascades［J］.J Ethnopharmacol,2021,265：113324.
［58］　ZHU X,WANG K,ZHANG K,TAN X,WU Z F,SUN S,et al.Tetramethylpyrazine protects retinal capillary endothelial cells (TR-iBRB2) against IL-1β-Induced nitrative/oxidative stress［J］.Int J Mol Sci,2015,16(9)：21775-21790.
［59］　HU Z,XIE C,YANG M,FU X,GAO H,LIU Y,et al.Add-on effect of Qiming granule,a Chinese patent medicine,in treating diabetic macular edema：A systematic review and Meta-analysis［J］.Phytother Res,2021,35(2)：587-602.
［60］　SADASIVAM R,PACKIRISAMY G,SHAKYA S,GOSWAMI M.Non-invasive multimodal imaging of diabetic retinopathy：a survey on treatment methods and nanotheranostics［J］.Nanotheranostics,2021,5(2)：166-181.
［61］　SHOVAL A,MARKUS A,ZHOU Z,LIU X,CAZELLES R,WILLNER I,et al.Anti-VEGF-aptamer modified C-Dots-A hybrid nanocomposite for topical treatment of ocular vascular disorders［J］.Small,2019,15(40)：e1902776.
［62］　MAHALING B,SRINIVASARAO D,RAGHU G,KASAM R K,BHANUPRAKASH R G,KATTI D S.A non-invasive nanoparticle mediated delivery of triamcinolone acetonide ameliorates diabetic retinopathy in rats［J］.Nanoscale,2018,10(35)：16485-16498.
［63］　LADDHA U D,KSHIRSAGAR S J.Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy：in vitro and in vivo evidences［J］.Heliyon,2020,6(8)：e04589.
［64］　DONG Y,WAN G,YAN P,QIAN C,LI F,PENG G.Fabrication of resveratrol coated Gold nanoparticles and investigation of their effect on diabetic retinopathy in streptozotocin induced diabetic rats［J］.J Photochem Photobiol B,2019,195：51-57.
［65］　AMADIO M,PASCALE A,CUPRI S,PIGNATELLO R,OSERA C,D AGATA V,et al.Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat［J］.Pharmacol Res,2016,111：713-720.

相似文献/References:

[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[5]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[6]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[7]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[8]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[9]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[10]李小璐 马雅玲.糖尿病视网膜病变大鼠视网膜VEGF和PEDF的动态表达[J].眼科新进展,2013,33(9):000.
[11]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[12]陈素芳 曾莉 邵毅. 非诺贝特在糖尿病视网膜病变中的应用进展[J].眼科新进展,2014,34(3):283.
[13]魏光杰,何佃菊.532nm绿激光格栅样光凝联合球内注药治疗糖尿病视网膜病变黄斑水肿[J].眼科新进展,2014,34(8):779.[doi:10.13389/j.cnki.rao.2014.0215]
　WEI Guang-Jie,HE Dian-Ju.532 run green grid laser photocoagulation combined with intravitreal Avastin injection for diabetic retinopathy macular edema[J].Recent Advances in Ophthalmology,2014,34(3):779.[doi:10.13389/j.cnki.rao.2014.0215]
[14]朱岩,汪军,孟忻,等. 非增殖期糖尿病视网膜病变黄斑水肿对脉络膜横断面面积的影响[J].眼科新进展,2015,35(7):683.[doi:10.13389/j.cnki.rao.2015.0187]
　ZHU Yan,WANG Jun,MENG Xin,et al. Effects of macular edema on choroidal cross sec on area in non-proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(3):683.[doi:10.13389/j.cnki.rao.2015.0187]
[15]洪婷婷,刘广峰,高新晓,等.糖尿病黄斑水肿玻璃体内注射康柏西普的短期疗效和椭圆体带完整性改变的观察[J].眼科新进展,2017,37(11):1053.[doi:10.13389/j.cnki.rao.2017.0266]
　HONG Ting-Ting,LIU Guang-Feng,GAO Xin-Xiao,et al.Short-term outcomes of intravitreal injection of conbercept for diabetic macular edema and restoration of ellipsoid zone[J].Recent Advances in Ophthalmology,2017,37(3):1053.[doi:10.13389/j.cnki.rao.2017.0266]
[16]徐静,唐晓娟,于健,等.糖尿病黄斑水肿患者病变程度与脉络膜厚度的关系[J].眼科新进展,2019,39(5):444.[doi:10.13389/j.cnki.rao.2019.0102]
　XU Jing,TANG Xiao-Juan,YU Jian,et al.Comparisons of choroidal thickness in relation to macular edema in type 2 diabetic patients[J].Recent Advances in Ophthalmology,2019,39(3):444.[doi:10.13389/j.cnki.rao.2019.0102]
[17]雷祥,范珂,崔红培,等.不同类型视网膜病变患者视网膜外层厚度变化研究[J].眼科新进展,2019,39(6):536.[doi:10.13389/j.cnki.rao.2019.0123]
　LEI Xiang,FAN Ke,CUI Hong-Pei,et al.Changes in outer retinal thickness in patients with different types of retinopathy[J].Recent Advances in Ophthalmology,2019,39(3):536.[doi:10.13389/j.cnki.rao.2019.0123]
[18]郑雨薇,蒋正轩,李恒,等.2型糖尿病患者干眼相关指标分析[J].眼科新进展,2022,42(11):874.[doi:10.13389/j.cnki.rao.2022.0180]
　ZHENG Yuwei,JIANG Zhengxuan,LI Heng,et al.Analysis of dry eye related factors in type 2 diabetic patients[J].Recent Advances in Ophthalmology,2022,42(3):874.[doi:10.13389/j.cnki.rao.2022.0180]
[19]朱婷婷,黄丹,张春元,等.玻璃体内注射康柏西普对糖尿病黄斑水肿患者和继发于视网膜静脉阻塞的黄斑水肿患者的疗效差异[J].眼科新进展,2023,43(1):053.[doi:10.13389/j.cnki.rao.2023.0011]
　ZHU Tingting,HUANG Dan,ZHANG Chunyuan,et al.Different efficacies of intravitreal injection of conbercept for diabetic macular edema and macular edema secondary to retinal vein obstruction[J].Recent Advances in Ophthalmology,2023,43(3):053.[doi:10.13389/j.cnki.rao.2023.0011]

备注/Memo

备注/Memo:
广东省基础与应用基础研究基金项目（编号：2021A1515010113）；白求恩· 默克糖尿病研究基金（编号：2018-133）； 广州市科技计划项目(编号：202102080008)
更新日期/Last Update: 2022-03-05